Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AbbVie has acquired Belgian biotech Syndesi Therapeutics for up to $1 billion, gaining a portfolio of SV2A modulators including Phase 1 lead candidate…
AbbVie has acquired Syndesi Therapeutics in a deal worth up to $1 billion, picking up a portfolio of SV2A modulators led by Phase 1 candidate SDI-118 for…
AbbVie has agreed to acquire Belgian biotech Syndesi Therapeutics in a deal worth up to $1 billion, expanding its neuroscience portfolio with a portfolio of…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
AbbVie acquired Syndesi Therapeutics for up to $1B ($130M upfront plus $870M in milestones). The deal added Syndesi's portfolio of SV2A modulators including lead molecule SDI-118, being evaluated for cognitive impairment in neuropsychiatric and neurodegenerative diseases such as Alzheimer's and major depressive disorder.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Syndesi Therapeutics SA (this deal) | 2022 | $1.0B | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2022 deals · AbbVie Inc. deals · Neurology deals